Our findings suggest that the lack of significant increase in the ALL model does not lead to changes in the clearance rates, while the dramatic and statistically significant increase in E-selectin binding in the AML model at relapse may play a role in altering the rate of clearance of relapse CLCs compared to untreated. This evidence concerns the gene SELE and acute lymphoblastic leukemia.